New Japanese approvals include Xarelto for stroke prevention
This article was originally published in Scrip
Executive Summary
Bayer's Xarelto (rivaroxaban) has become the second of the novel anticoagulants to be approved in Japan for the prevention of stroke and systemic embolism in patients with non-valvular atrial fibrillation.